SCHEMBL8405115

SCHEMBL8405115

CC(COc1ccc(CC2SC(=O)N(C(c3ccccc3)(c3ccccc3)c3ccccc3)C2=O)cc1)NC(=O)OC(C)(C)C

nearest known ligand 0.39

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
MTNR1A P48039 3/20 0.38
MTNR1B P49286 3/20 0.38
HDAC8 Q9BY41 1/20 0.37
PTPN1 P18031 2/20 0.36
GPR88 Q9GZN0 1/20 0.36
PPARG P37231 2/20 0.36
PPARA Q07869 1/20 0.36
ITGB3 P05106 1/20 0.35
ITGA2B P08514 1/20 0.35
BCL2 P10415 1/20 0.35
CTSS P25774 1/20 0.35
CTSK P43235 1/20 0.35
HRH2 P25021 1/20 0.35
HRH1 P35367 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8405118 1.00 MTNR1A (0.38) MTNR1AMTNR1BHDAC8PTPN1GPR88
SCHEMBL8306640 0.91 CTRB1 (0.41) HDAC8GPR88ITGB3ITGA2B
SCHEMBL8306638 0.91 CTRB1 (0.41) HDAC8GPR88ITGB3ITGA2B
SCHEMBL8306634 0.91 CTRB1 (0.41) HDAC8GPR88ITGB3ITGA2B
SCHEMBL1130749 0.79 PPARG (0.47) PTPN1PPARG
SCHEMBL8309388 0.79 PPARG (0.44) PPARG
SCHEMBL8857154 0.77 PPARG (0.43) PPARG
SCHEMBL8304179 0.76 MCL1 (0.41) PPARG
SCHEMBL507001 0.74 MTNR1A (0.66) MTNR1AMTNR1BPPARACTSSCTSK
SCHEMBL30241501 0.74 MTNR1A (0.66) MTNR1AMTNR1BPPARACTSSCTSK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-5977374-A 5-(4-hydroxy-OR 4-acetoxy-benzyl)-3- triphenylmethylthiazolidine-2,4-dione and method for producing same SANKYO COMPANY, LIMITED (JP) 1999-11-02 US disclosed
EP-0590793-B1 Oxazolidine derivatives having anti-diabetic and anti-obesity properties, their preparation and their therapeutic uses SANKYO CO (JP) 1999-10-13 EP disclosed
US-5635534-A 1-PHENYL-2-(2-PHENYLOXY OR THIO)-1-METHYLETHYL)AMINOETHANOL DERIVATIVES; ALDOSE REDUCTASE INHIBITORS; NONTOXIC; ANTIDIABETIC,-OBESITY,-LIPEMIC AND HYPOGLYCEMIC AGENTS SANKYO COMPANY, LIMITED (JP) 1997-06-03 US disclosed
US-5576340-A Aromatic amino-alcohol derivatives having anti-diabetic and anti-obesity properties, their preparation and their therapeutic uses SANKYO COMPANY, LIMITED (JP) 1996-11-19 US disclosed
EP-0543662-B1 Aromatic amino-alcohol derivatives having anti-diabetic and anti-obesity properties, their preparation and their therapeutic uses SANKYO CO (JP) 1996-09-18 EP disclosed
US-5436257-A Low toxicity SANKYO COMPANY, LIMITED (JP) 1995-07-25 US disclosed
EP-0590793-A1 Oxazolidine derivatives having anti-diabetic and anti-obesity properties, their preparation and their therapeutic uses SANKYO COMPANY LIMITED (JP) 1994-04-06 EP disclosed
EP-0543662-A2 Aromatic amino-alcohol derivatives having anti-diabetic and anti-obesity properties, their preparation and their therapeutic uses Sankyo Company Limited (JP) 1993-05-26 EP disclosed